The US Centers for Medicare and Medicaid Services (CMS) has published its final 2007 marketing guidelines for the Medicare prescription drug plans. These reflect the results of public consultations, with clarification of some policies and an attempt by the CMS to address potential problems in draft regulations.
The final version of the marketing guidelines deals with issues related to co-branding, the role of marketing representatives, submission procedures for marketing materials for approval by the CMS, member identification cards, information about employers and labor unions, as well as value-added items and services, according to a statement by the agency.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze